Myelofibrosis
Advertisement
Interprofessional team-based care is the standard for patients undergoing HSCT. But who belongs on the team?
Higher baseline quality of life independently predicted longer overall survival in patients with myelofibrosis.
Pacritinib was found to be more effective than best available treatment at reducing spleen volume in myelofibrosis patients.
Adding navitoclax to ruxolitinib treatment in patients with persistent or progressive myelofibrosis led to durable splee
Myelofibrosis patients treated with fludarabine and busulfan along with TBI saw reduction in graft failure.
A trial examined weekly administration of LCL161 therapy in a large, high-risk, older study population with myelofibrosis ...
An analysis published in Annals of Hematology sought to add real-world context to findings from the phase II MYF2001 trial, ...
In a study published in Blood, investigators sought to define a new therapeutic target for the treatment of myelofibrosis ...
The JAK1/2 inhibitor ruxolitinib is a potent immunomodulator and effectively treats myeloproliferative disease such as ...
According to results from the ROMEI trial, patients with myelofibrosis receiving the oral JAK1/2 inhibitor ruxolitinib ...
Palbociclib, a drug approved to treat HR-positive and HER2-negative breast cancer, could lead to improvement in symptoms of ...
A phase II study of single-agent nivolumab in patients with myelofibrosis was terminated early, after failing to meet its ...
The JAK1/2 inhibitor ruxolitinib induced durable improvements in patients with primary and secondary myelofibrosis in the ...
A study published in the European Journal of Hematology evaluated the effects of various patient and clinical factors on ...
An analysis of data from the large, prospective, multinational, phase IIIb JUMP trial evaluated patient and disease ...
While ruxolitinib improves outcomes in patients with myelofibrosis (MF), some patients’ disease may have a suboptimal ...
A study published in Transplant and Cellular Therapy assessed outcomes in patients with myelofibrosis (MF) who choose to ...
A study presented as part of the ASH 2020 Annual Meeting found that use of fedratinib for 24 or more weeks was well-tolerated ...
Interferon-alpha (rIFN?) is the only disease-modifying treatment option for polycythemia vera (PV). A study published in ...
The Janus kinase (JAK) inhibitor ruxolitinib was U.S. Food and Drug Administration-approved for patients with high-risk ...
Advertisement
670 Madison Ave.
Manalapan, NJ 07726